Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN

Watchlist Manager
Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Watchlist
Price: 50.36 USD -3.95% Market Closed
Market Cap: 5B USD
Have any thoughts about
Biohaven Pharmaceutical Holding Company Ltd?
Write Note

Wall Street
Price Targets

BHVN Price Targets Summary
Biohaven Pharmaceutical Holding Company Ltd

Wall Street analysts forecast BHVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BHVN is 66.54 USD with a low forecast of 55.55 USD and a high forecast of 84 USD.

Lowest
Price Target
55.55 USD
10% Upside
Average
Price Target
66.54 USD
32% Upside
Highest
Price Target
84 USD
67% Upside

BHVN Last Price Targets
Biohaven Pharmaceutical Holding Company Ltd

The latest public price target was made on Oct 15, 2024 by Jason Gerberry from Bank of America Securities , who expects BHVN stock to rise by 29% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Jason Gerberry
Bank of America Securities
65 USD
Upside 29%
4 weeks ago
Oct 15, 2024
BofA Securities Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
StreetInsider
Marc Goodman
Leerink Partners
60 USD
Upside 19%
1 month ago
Sep 24, 2024
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Leerink Partners
StreetInsider
Leonid Timashev
RBC Capital
68 USD
Upside 35%
1 month ago
Sep 24, 2024
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at RBC Capital
StreetInsider
Douglas Tsao
H.C. Wainwright
59 USD
Upside 17%
1 month ago
Sep 24, 2024
H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
StreetInsider
Jason Gerberry
Bank of America Securities
62 USD
Upside 23%
1 month ago
Sep 24, 2024
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $62 at BofA Securities
StreetInsider
Brian Skorney
Robert W. Baird
60 USD
Upside 19%
1 month ago
Sep 23, 2024
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Baird
StreetInsider
Thomas Shrader
BTIG
59 USD
Upside 17%
1 month ago
Sep 23, 2024
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN), PT $59
StreetInsider
Amy Li
Jefferies
57 USD
Upside 13%
1 month ago
Sep 16, 2024
Biohaven initiated with a Buy at Jefferies
TheFly
William Pickering
Tudor Pickering
55 USD
Upside 9%
2 months ago
Sep 4, 2024
Biohaven initiated with an Outperform at Bernstein
TheFly
Terence Flynn
Morgan Stanley
58 USD
Upside 15%
3 months ago
Jul 24, 2024
Biohaven initiated with an Overweight at Morgan Stanley
TheFly
Brian Skorney
Robert W. Baird
58 USD
Upside 15%
5 months ago
May 29, 2024
Biohaven selloff following degrader data 'overdone,' says Baird
TheFly
Leonid Timashev
RBC Capital
59 USD
Upside 17%
5 months ago
May 29, 2024
RBC Capital Defending Biohaven Pharmaceutical Holding (BHVN): 'We Would Be Buyers on Weakness'
StreetInsider
Show More Price Targets
Show Less Price Targets
Jason Gerberry
Bank of America Securities
Price Target 65 USD
Upside/Downside 29%
View Source
Marc Goodman
Leerink Partners
Price Target 60 USD
Upside/Downside 19%
View Source
Leonid Timashev
RBC Capital
Price Target 68 USD
Upside/Downside 35%
View Source
Douglas Tsao
H.C. Wainwright
Price Target 59 USD
Upside/Downside 17%
View Source
Jason Gerberry
Bank of America Securities
Price Target 62 USD
Upside/Downside 23%
View Source
Brian Skorney
Robert W. Baird
Price Target 60 USD
Upside/Downside 19%
View Source
Thomas Shrader
BTIG
Price Target 59 USD
Upside/Downside 17%
View Source
Amy Li
Jefferies
Price Target 57 USD
Upside/Downside 13%
View Source
William Pickering
Tudor Pickering
Price Target 55 USD
Upside/Downside 9%
View Source
Terence Flynn
Morgan Stanley
Price Target 58 USD
Upside/Downside 15%
View Source
Brian Skorney
Robert W. Baird
Price Target 58 USD
Upside/Downside 15%
View Source
Leonid Timashev
RBC Capital
Price Target 59 USD
Upside/Downside 17%
View Source
Show More Price Targets
Show Less Price Targets
Biohaven Pharmaceutical Holding Company Ltd Competitors:
Price Targets
STTK
Shattuck Labs Inc
62% Upside
LGVN
Longeveron Inc
269% Upside
FOLD
Amicus Therapeutics Inc
70% Upside
NTLA
Intellia Therapeutics Inc
314% Upside
688739
Liaoning Chengda Biotechnology Co Ltd
42% Upside
ALKS
Alkermes Plc
22% Upside
CYTK
Cytokinetics Inc
50% Upside

Revenue
Forecast

Revenue Estimate
Biohaven Pharmaceutical Holding Company Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Biohaven Pharmaceutical Holding Company Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Biohaven Pharmaceutical Holding Company Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BHVN's stock price target?
Price Target
66.54 USD

According to Wall Street analysts, the average 1-year price target for BHVN is 66.54 USD with a low forecast of 55.55 USD and a high forecast of 84 USD.

Back to Top